Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EBIT (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of EBIT data on record, last reported at -$16377.0 in Q4 2025.

  • For Q4 2025, EBIT fell 183.52% year-over-year to -$16377.0; the TTM value through Dec 2025 reached -$154024.0, down 1634.11%, while the annual FY2025 figure was -$154024.0, 1634.11% down from the prior year.
  • EBIT reached -$16377.0 in Q4 2025 per ACBM's latest filing, up from -$115099.0 in the prior quarter.
  • Across five years, EBIT topped out at $6.9 million in Q4 2023 and bottomed at -$4.0 million in Q3 2022.
  • Average EBIT over 5 years is -$974938.8, with a median of -$86045.0 recorded in 2021.
  • Peak YoY movement for EBIT: surged 2962.54% in 2021, then plummeted 6793.35% in 2022.
  • A 5-year view of EBIT shows it stood at $2.2 million in 2021, then tumbled by 276.85% to -$3.9 million in 2022, then soared by 276.35% to $6.9 million in 2023, then tumbled by 99.72% to $19608.0 in 2024, then tumbled by 183.52% to -$16377.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$16377.0 in Q4 2025, -$115099.0 in Q3 2025, and -$13614.0 in Q2 2025.